Guggenheim cuts Insmed stock price target on model changes to $201

Guggenheim reduced its price target for Insmed Inc. (INSM) to $201 from $205, citing model changes after Q3 2026 results. Brinsupri sales hit $400.1M, exceeding expectations, driving 240% revenue growth. Insmed's market cap is $24.7B. Arikayce also beat expectations. Goldman Sachs and Stifel maintained Buy ratings with targets of $194 and $195, respectively.

Original reporting
Published Nov 2, 2026, 12:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 1:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$INSM
Neutral
medium confidence
Mentioned
$INSM
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$INSMNeutralLow
01

Why it matters

Analyst target adjustments reflect mixed view of growth versus profitability.

02

Market read

Post‑earnings analyst revisions provide modest guidance for traders.

03

What to watch

Potential pipeline progress and upcoming regulatory approvals could offset valuation concerns.

Relevance 5/10Novelty 3/10Timing: after earnings release

Background

Insmed reported Q3 2026 revenue of $524.4 million, beating forecasts, but EPS missed expectations.

Company-level read

Ticker impact

$INSMNeutralMedium confidence
Context

Guggenheim lowered its price target on Insmed to $201 from $205 following the company's Q3 2026 earnings release.

Expected impact

likely pressure as the market prices in the lower target

Evidence & confidence

Target cut reflects concerns about valuation despite strong revenue; investors may trim positions.

Market effects

Biotech sector may see modest re‑rating as analysts reassess valuation multiples.

Limited to US‑listed biotech stocks.

Minimal global impact.

Counterpoint

Some investors may view the target cut as an over‑reaction given the strong revenue beat.

Key entities

  • Guggenheim

    Equity research firm that cut the price target.

  • Goldman Sachs

    Maintained a $194 price target.

  • Stifel

    Adjusted target to $195.

Related articles

$INSMHighAI 8/10

Why Did Insmed Stock Jump?

Insmed (INSM) shares rose 15.1% on October 29, 2026, after reporting Q3 2026 results. Revenue of $524.4M beat estimates, but loss per share was wider. BRINSUPRI revenue grew 29% QoQ, and guidance was raised. R&D and sales costs increased 40% YoY. The stock is down 32.5% over the past year.

$INSMHighAI 9/10

Goldman Sachs reiterates Insmed stock rating on Brinsupri beat

Goldman Sachs maintained a Buy rating and $194 price target for Insmed (INSM) after its quarterly results beat estimates. Brinsupri revenue was $400.1M, exceeding expectations. Insmed raised its 2026 guidance for Brinsupri to $1.35B-$1.40B. The stock rose 19.5% to $111.59. Analysts have revised earnings upwards, with price targets ranging from $165 to $243.

$INSMMed

Insmed Inc (INSM) Q3 2026 Earnings Call Highlights: Brinsupri Hits Blockbuster Status

Insmed Inc (INSM) reported positive Q3 2026 earnings, with Brinsupri showing strong persistency and revenue trends. The company expects cash flow positivity in 2027 and provided updates on TPIP trials and Erakase's label expansion. Dr. Martina Flammer highlighted growth opportunities in comorbid COPD and asthma bronchiectasis, with data expected in mid-2027. Insmed also discussed AI use for patient identification and the potential impact of real-world studies.

$INSMMedAI 8/10

What Insmed (INSM) Said on Its Q3 Earnings Call

Insmed (INSM) reported Q3 earnings, highlighting AI diagnostic tools for bronchiectasis, expected to share findings in 2027. FDA granted priority review for ARIKAYCE's sNDA, with a target action date of Jan. 28, 2027. The company expects cash-flow positivity in 2027. Insmed also provided updates on its pipeline, including TPIP and INS1033 programs. Cost of product revenues was $78.2 million, or 14.9% of revenue, with combined R&D and SG&A expenses up 40% year over year.

$INSMHighAI 8/10

Insmed (INSM) Q3 2026 Earnings Call Transcript

Insmed (INSM) reported Q3 2026 revenue of $400.1M for BRINSUPRI, up 29% sequentially. The company raised its 2026 revenue guidance to $1.35B-$1.4B. Insmed expects its lead respiratory assets to exceed $14B in peak sales, with BRINSUPRI potentially reaching $7B+ and TPIP $6B+.